CXCR4 Antagonist

CXCR4 Antagonists (33):

Cat. No.	Product Name	Effect	Purity

HY-10046

Plerixafor	Antagonist	≥98.0%
Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC₅₀ of 44 nM.

HY-50912

Plerixafor octahydrochloride	Antagonist	≥98.0%
Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective CXCR4 antagonist with an IC₅₀ of 44 nM.

HY-P0171

Motixafortide	Antagonist	99.03%
Motixafortide (BKT140 4-fluorobenzoyl) is a novel CXCR4 antagonist with an IC₅₀ vakue of ～1 nM.

HY-50101A

Mavorixafor trihydrochloride	Antagonist	98.69%
Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally available CXCR4 antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 and 9 nM, respectively.

HY-P99272

Ulocuplumab	Antagonist
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody.

HY-P4111

Peptide R	Antagonist
Peptide R, a cyclic peptide, is a specific CXCR4 antagonist.

HY-101458A

IT1t dihydrochloride	Antagonist	99.89%
IT1t dihydrochloride is a potent CXCR4 antagonist; inhibits CXCL12/CXCR4 interaction with an IC₅₀ of 2.1 nM.

HY-P1682A

Balixafortide TFA	Antagonist	99.78%
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM.

HY-19867A

Burixafor hydrobromide	Antagonist	≥98.0%
Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent antagonist of CXCR4 and a well anti-angiogenic drug that is of potential value in treating choroid neovascularization.

HY-15478

WZ811	Antagonist	≥98.0%
WZ811 is an orally active, highly potent competitive antagonist of CXCR4.

HY-15971

AMD 3465 hexahydrobromide	Antagonist	≥98.0%
AMD 3465 hexahydrobromide (GENZ-644494 hexahydrobromide) is a potent antagonist of CXCR4, inhibits binding of 12G5 mAb and CXCL12^AF647 to CXCR4, with IC₅₀s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of X4 HIV strains (IC₅₀: 1-10 nM), but has no effect on CCR5-using (R5) viruses.

HY-P1104A

FC131 TFA	Antagonist	98.38%
FC131 TFA is a CXCR4 antagonist, inhibits [¹²⁵I]-SDF-1 binding to CXCR4, with an IC₅₀ of 4.5 nM.

HY-13696

MSX-122	Antagonist
MSX-122 is an orally active partial antagonist of CXCR4, inhibiting CXCR4/CXCL12 actions, with an IC₅₀ of ∼10 nM.

HY-114244

USL311	Antagonist	99.97%
USL311 is a potent and selective CXCR4 antagonist, with anti-tumor activity.

HY-P1103

CTCE-9908	Antagonist	99.69%
CTCE-9908 is a potent and selective CXCR4 antagonist.

HY-103010

MSX-130	Antagonist	98.00%
MSX-130 is a CXCR4 antagonist.

HY-101458

IT1t	Antagonist
IT1t is a potent CXCR4 antagonist; inhibits CXCL12/CXCR4 interaction with an IC₅₀ of 2.1 nM.

HY-50101

Mavorixafor	Antagonist
Mavorixafor (AMD-070) is a potent, selective and orally available CXCR4 antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 and 9 nM, respectively.

HY-122058A

KRH-3955 hydrochloride	Antagonist
KRH-3955 hydrochloride is an orally bioavailable CXCR4 antagonist.

HY-P1104

FC131	Antagonist
FC131 is a potent CXCR4 antagonist.

Name
Email *

	Sorry, but the email address you supplied was invalid.